S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024

Progyny (PGNY) Stock Price, News & Analysis

$39.87
+1.20 (+3.10%)
(As of 02/26/2024 ET)
Today's Range
$38.81
$40.59
50-Day Range
$35.65
$41.62
52-Week Range
$29.44
$44.95
Volume
907,346 shs
Average Volume
664,054 shs
Market Capitalization
$3.82 billion
P/E Ratio
76.67
Dividend Yield
N/A
Price Target
$48.60

Progyny MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
21.9% Upside
$48.60 Price Target
Short Interest
Bearish
7.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Progyny in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$12.05 M Sold Last Quarter
Proj. Earnings Growth
19.30%
From $0.57 to $0.68 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

332nd out of 942 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

3rd out of 5 stocks


PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Progyny (PGNY) to Release Quarterly Earnings on Tuesday
PGNY Mar 2024 40.000 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Progyny Expands its Leadership Team
Truist Financial Keeps Their Buy Rating on Progyny (PGNY)
Progyny Inc CFO Mark Livingston Sells 12,368 Shares
Does Progyny (PGNY) have a Long Runway for Growth?
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/26/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
393
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$48.60
High Stock Price Target
$57.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+21.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$30.36 million
Pretax Margin
5.67%

Debt

Sales & Book Value

Annual Sales
$786.91 million
Cash Flow
$0.36 per share
Book Value
$4.06 per share

Miscellaneous

Free Float
82,419,000
Market Cap
$3.82 billion
Optionable
Optionable
Beta
1.51

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report














PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

9 Wall Street analysts have issued 12 month price targets for Progyny's stock. Their PGNY share price targets range from $45.00 to $57.00. On average, they anticipate the company's share price to reach $48.60 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 at the beginning of 2024. Since then, PGNY shares have increased by 7.2% and is now trading at $39.87.
View the best growth stocks for 2024 here
.

Are investors shorting Progyny?

Progyny saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 6,220,000 shares, an increase of 18.5% from the January 15th total of 5,250,000 shares. Based on an average daily volume of 722,300 shares, the short-interest ratio is presently 8.6 days. Currently, 7.5% of the company's shares are sold short.
View Progyny's Short Interest
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our PGNY earnings forecast
.

How can I listen to Progyny's earnings call?

Progyny will be holding an earnings conference call on Tuesday, February 27th at 4:45 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 973-528-0005 with passcode "265484".

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) posted its quarterly earnings results on Tuesday, November, 7th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $280.90 million for the quarter, compared to the consensus estimate of $271.20 million. Progyny had a net margin of 5.03% and a trailing twelve-month return on equity of 11.64%. The firm's revenue was up 36.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.13 earnings per share.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.63%), International Assets Investment Management LLC (6.13%), Clearbridge Investments LLC (3.64%), Jennison Associates LLC (2.64%), Riverbridge Partners LLC (2.10%) and Riverbridge Partners LLC (1.91%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Michael E Sturmer, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 2/27/2024 by MarketBeat.com Staff